Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with advanced non-small cell lung cancer (a type of lung cancer) that has been confirmed by laboratory testing and carries a specific genetic marker called ALK-positive, detected through a genetic sequencing test.
- People who have been diagnosed with cancer that has spread to the brain, or where spread to the brain is suspected.
- People for whom the study drug, iruplinalib, has been proposed as a treatment by their doctor.
- People whose general health and ability to carry out daily activities falls within a certain range, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
- People whose liver, kidneys, bone marrow, and other organs are functioning at an adequate level based on blood tests.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have serious digestive system disease, or other uncontrolled illnesses or infections.
- People who have a mental health condition or substance use issue at the time of screening that may affect their ability to follow the trial requirements.
- People who have fluid build-up around the lungs or in the abdomen that requires treatment or that the trial doctor considers uncontrollable at the time of screening.
- People who have experienced a blood clot or related event — such as a stroke, deep vein clot in the leg, or a blood clot in the lungs — within the six months before starting the study drug.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Cerebrospinal fluid levels of Immune cells,inflammatory cytokines,immunoglobulins and cell adhesion molecules
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.